This panel analyses 72 genes associated with the reported increased risk in at least one study of one or more of the following hereditary cancers: breast, colorectal, endometrial, gastric, melanoma, ovarian, pancreatic, prostate, renal, skin, thyroid, and uterine. The test can be used to confirm the presence of a genetic variant in already diagnosed cancer… Read more »
Kit Category: For Providers
Bulk and wholesale COVID-19 test kits The COVID-19 antigen rapid test is used for the detection of SARS-CoV-2 that causes COVID-19. It uses the latest lateral flow immunoassay technology for the detection of nucleocapsid protein antigen in individuals with known or suspected COVID-19. This rapid test accurately delivers results within 15 minutes, making it suitable… Read more »
Genetic risk test associated with hereditary common cancers This test provides a comprehensive analysis of an individual’s genetic risk of developing common hereditary cancers. It analyses 84 genes associated with hereditary cancers across 8 major organ systems. It is designed for individuals who have a personal or family history of mixed cancers affecting multiple organ… Read more »
Genetic risk test associated with colorectal cancer This test analyses 20 genes that are associated with colorectal cancer, and the option of a further 10 genes that have preliminary evidence of an association with this cancer type. It is designed for early detection to help guide the right treatment, reduce the risk of recurrence and… Read more »
Genetic risk test associated with prostate cancer This test analyses 19 genes that are associated with increased hereditary risk of developing prostate cancer. It is designed to identify early detection and help guide the right treatment pathway, reduce the risk of reoccurrence and increase the chances of survival. It is suitable for men who have… Read more »
Genetic testing to help guide breast cancer treatment This test analyses 12 genes known to significantly increase the risk of developing breast and ovarian cancer as a second primary. It identifies genetic variants in the BRCA1 and BRCA2 genes which are associated with Hereditary Breast and Ovarian Cancer syndrome, along with a further 10 established… Read more »
Personalise your patient’s cancer care with molecular testing Caris MI Tumor Seek™ is a comprehensive molecular profiling service that reveals the unique characteristics of a patient’s cancer to help guide more precise and personalised treatment choices. Using advanced molecular profiling and Next Generation Sequencing (NGS) the DNA and RNA of the tumour are precisely analysed… Read more »
Genetic testing for prostate cancer risk Antegenes® Prostate assesses an individual’s risk of developing prostate cancer based on the technology of polygenic risk scores. It uses data from 121 genome-wide single nucleotide polymorphisms (SNPs) to help guide cancer screening and risk-reduction measures for prostate cancer. The test is recommended for men between the ages of 40… Read more »
AnteCRC is a genetic test that assesses your risk of developing colorectal cancer. This test defines personal genetic predisposition for colorectal cancer. Based on personal risk level, it is possible to give scientific and practical personalised recommendations to prevent or detect colorectal cancer at an early stage when it is still treatable.
AnteMEL is a genetic test that assesses your risk of developing skin melanoma. This test defines personal genetic predisposition for melanoma. Based on personal risk level, it is possible to give scientific and practical personalised recommendations for melanoma risk management and screening.